Forsta AP Fonden Sells 6,400 Shares of CVS Health Corporation $CVS

Forsta AP Fonden trimmed its holdings in shares of CVS Health Corporation (NYSE:CVS) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 270,500 shares of the pharmacy operator’s stock after selling 6,400 shares during the period. Forsta AP Fonden’s holdings in CVS Health were worth $21,467,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Ares Financial Consulting LLC bought a new stake in CVS Health in the fourth quarter valued at approximately $29,000. Dogwood Wealth Management LLC increased its stake in CVS Health by 93.7% in the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 179 shares in the last quarter. GoalVest Advisory LLC bought a new stake in CVS Health in the fourth quarter valued at approximately $32,000. Finally, MidAtlantic Capital Management Inc. bought a new stake in CVS Health in the fourth quarter valued at approximately $35,000. 80.66% of the stock is owned by institutional investors.

Insider Buying and Selling at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce’s Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

Wall Street Analysts Forecast Growth

CVS has been the subject of several recent analyst reports. Leerink Partners reaffirmed an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Truist Financial upped their target price on shares of CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. UBS Group upped their target price on shares of CVS Health from $97.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Piper Sandler lowered their target price on shares of CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a research note on Tuesday, March 31st. Finally, Argus upped their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.88.

CVS Health Stock Down 2.2%

CVS Health stock opened at $90.97 on Friday. The stock has a market capitalization of $116.06 billion, a PE ratio of 40.07, a price-to-earnings-growth ratio of 0.89 and a beta of 0.60. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a 50 day moving average of $82.07 and a 200-day moving average of $79.55.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter in the prior year, the company earned $2.25 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio is presently 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.